Show simple item record

In vitro activities of five quinolones against Chlamydia pneumoniae.

dc.contributor.authorHammerschlag, M R
dc.contributor.authorHyman, C L
dc.contributor.authorRoblin, P M
dc.date.accessioned2023-06-26T17:25:35Z
dc.date.available2023-06-26T17:25:35Z
dc.date.issued1992-03
dc.identifier.citationHammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1992 Mar;36(3):682-3. doi: 10.1128/AAC.36.3.682. PMID: 1320366; PMCID: PMC190581.en_US
dc.identifier.issn0066-4804
dc.identifier.pmid1320366
dc.identifier.urihttp://hdl.handle.net/20.500.12648/10322
dc.description.abstractThe in vitro susceptibilities of 10 strains of Chlamydia pneumoniae were determined for five quinolones, including ciprofloxacin, ofloxacin, fleroxacin, temafloxacin, and sparfloxacin. Sparfloxacin was the most active compound tested, followed by ofloxacin and temafloxacin. Ciprofloxacin and fleroxacin were the least active. The use of HEp-2 cells for testing C. pneumoniae resulted in larger inclusions but essentially the same endpoints as were seen with use of HeLa 229 cells.
dc.language.isoenen_US
dc.relation.urlhttps://journals.asm.org/doi/10.1128/AAC.36.3.682en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleIn vitro activities of five quinolones against Chlamydia pneumoniae.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAntimicrobial agents and chemotherapyen_US
dc.source.volume36
dc.source.issue3
dc.source.beginpage682
dc.source.endpage3
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-06-26T17:25:36Z
html.description.abstractThe in vitro susceptibilities of 10 strains of Chlamydia pneumoniae were determined for five quinolones, including ciprofloxacin, ofloxacin, fleroxacin, temafloxacin, and sparfloxacin. Sparfloxacin was the most active compound tested, followed by ofloxacin and temafloxacin. Ciprofloxacin and fleroxacin were the least active. The use of HEp-2 cells for testing C. pneumoniae resulted in larger inclusions but essentially the same endpoints as were seen with use of HeLa 229 cells.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentPediatricsen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAntimicrobial agents and chemotherapy


Files in this item

Thumbnail
Name:
aac.36.3.682.pdf
Size:
359.6Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International